HLB Pharmaceutical Co. Ltd (047920) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.015x

Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.86 Billion ≈ $1.26 Million USD) by net assets (₩120.95 Billion ≈ $81.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of HLB Pharmaceutical Co. Ltd for the company's overall valuation and market capitalisation.

HLB Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how HLB Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

HLB Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HLB Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency. Explore 047920 cash flow quality index to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Gia Lai Electricity JSC VN:GEG	0.076x
Electreon Wireless Ltd TA:ELWS	-0.154x
Sri Rejeki Isman(Sritex)PT JK:SRIL	0.007x
Huons Global Co. Ltd KQ:084110	0.027x
Thrace Plastics Holding and Commercial S.A AT:PLAT	0.033x
Pro-Hawk TWO:8083	0.078x
Helloworld Travel Ltd AU:HLO	-0.022x
Byggma OL:BMA	-0.001x

Annual Cash Flow Conversion Efficiency for HLB Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of HLB Pharmaceutical Co. Ltd from 2014 to 2024. View 047920 live share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩116.40 Billion ≈ $78.88 Million	₩6.84 Billion ≈ $4.64 Million	0.059x	+128.28%
2023-12-31	₩88.15 Billion ≈ $59.74 Million	₩-18.32 Billion ≈ $-12.41 Million	-0.208x	-546.24%
2022-12-31	₩85.93 Billion ≈ $58.23 Million	₩-2.76 Billion ≈ $-1.87 Million	-0.032x	-90.74%
2021-12-31	₩78.38 Billion ≈ $53.12 Million	₩-1.32 Billion ≈ $-895.45K	-0.017x	-86.48%
2020-12-31	₩44.62 Billion ≈ $30.24 Million	₩-403.36 Million ≈ $-273.35K	-0.009x	-111.60%
2019-12-31	₩17.36 Billion ≈ $11.76 Million	₩1.35 Billion ≈ $917.12K	0.078x	+174.56%
2018-12-31	₩17.00 Billion ≈ $11.52 Million	₩-1.78 Billion ≈ $-1.20 Million	-0.105x	-124.00%
2017-12-31	₩16.80 Billion ≈ $11.39 Million	₩-784.30 Million ≈ $-531.51K	-0.047x	-313.95%
2016-12-31	₩18.90 Billion ≈ $12.81 Million	₩-213.11 Million ≈ $-144.42K	-0.011x	+82.16%
2015-12-31	₩12.18 Billion ≈ $8.25 Million	₩-769.59 Million ≈ $-521.54K	-0.063x	-119.72%
2014-12-31	₩4.81 Billion ≈ $3.26 Million	₩1.54 Billion ≈ $1.05 Million	0.320x	--

About HLB Pharmaceutical Co. Ltd

KQ:047920 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$174.93 Million

₩258.13 Billion KRW

Market Cap Rank

#17185 Global

#675 in Korea

Share Price

₩7870.00

Change (1 day)

+3.01%

52-Week Range

₩6170.00 - ₩20900.00

All Time High

₩41100.00